Evaluation of Foveal Vasculature by Optical Coherence Tomography Angiography after Pan-Retinal Photocoagulation versus Intravitreal Anti-VEGF Injections

Autor: Hamid Riazi-Esfahani, Amin Ahmadi, Reza Sadeghi, Masoud Mirghorbani, Fariba Ghassemi, Mohammad Zarei, Hassan Khojasteh, Nikoo Bayan, Hooshang Faghihi, Elias Khalili Pour, Ahmad Mirshahi
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Journal of Ophthalmic & Vision Research, Vol 19, Iss 3, Pp 000-000 (2024)
Druh dokumentu: article
ISSN: 2008-2010
2008-322X
DOI: 10.18502/jovr.v19i3.13622
Popis: Abstract Purpose: This study aimed to compare macular vascular changes one and three months after treatment with either panretinal photocoagulation (PRP) or intravitreal bevacizumab (IVB). Methods: A total of 62 eyes with very severe non-proliferative diabetic retinopathy or early proliferative diabetic retinopathy without center-involved diabetic macular edema, were included in this retrospective study. Thirty-nine eyes were allocated to the PRP group, while 23 eyes were treated with IVB. Optical coherence tomography angiography (OCTA) was performed to measure foveal avascular zone (FAZ) characteristics as well as the densities of superficial and deep capillary plexuses (SCP and DCP). Results: In the IVB group, the FAZ area and perimeter expanded at month one but returned to baseline level after three months. In the PRP group, however, the FAZ area and perimeter were rather steady. Changes in the FAZ area were significantly different between the treatment groups at month one (P = 0.02), but not at month three (P = 0.31). There was no significant difference in the change in FAZ circularity index between the two groups at each time point (P = 0.55 and P = 0.31). Similarly, changes in SCP density were not statistically significant between the two groups at both time points (all Ps > 0.05). A comparison of the two treatment arms based on the mean change in DCP density revealed a significant difference at month one, but not at month three (P = 0.01 and P = 0.49, respectively). Conclusion: Although bevacizumab and PRP have different short-term macular vascular responses, both therapies have the ability to normalize or stabilize vascular measures over time.
Databáze: Directory of Open Access Journals
Externí odkaz: